The essential journalist news source
Back
6.
November
2018.
Further accolades for MediSieve, finalists at the H&F Brilliant Business Awards

Further accolades for MediSieve, finalists at the Hammersmith & Fulham Brilliant Business Awards 2018

 Medical device firm MediSieve is celebrating after making the shortlist of this year's Hammersmith and Fulham Brilliant Business Awards. Nominated in the Best Tech Start-Up category, they were put forward by Upstream, a joint venture between Imperial College and Hammersmith & Fulham Council.

All businesses and social enterprises within the West London borough could enter, and winners are set to be named at next month's gala presentation in Hammersmith's Grand Assembly Hall. The ceremony is scheduled for November 7. 

Dr George Frodsham, CEO of MediSieve, said: "Clearly we are thrilled to have made the shortlist in these sought-after awards, and the whole team will be attending the ceremony. 

"We know that the expert judging panel has looked at high-quality entries from more businesses than ever before, which makes being a finalist even more special. Even if we don't win on the night, we're genuinely thrilled to have got this far." 

Judges in the Best Tech Start-Up category are looking for outstanding potential, technological innovation and creativity, as well as clear evidence that the technology in question will provide a service people actually need. Something that MediSieve has in abundance.

Along with the 13 categories which are judged by an expert panel, there are three public vote categories in the competition, which aims to recognise entrepreneurship and hard work in this part of London. 

MediSieve was established in 2015, as an independent company, having spun off from University College London. Its magnetic blood filtration system can specifically and selectively remove disease-causing agents from the blood. The company is based in White City, at the Imperial College Translation and Innovation Hub. 

MediSieve's technology potentially has the ability to transform the way blood-borne diseases such as leukaemia, malaria and sepsis are treated. 

The firm's pioneering device involves the targeting of the specific components which are behind these diseases, before taking them out of the patient's bloodstream. 

Clinicians are thereby provided with a tool with which they can target and get rid of infected cells, toxins, pathogens, cytokines and other elements.

ENDS


NOTES FOR EDITORS

For interviews and photographs, contact pr@redheadpr.co.uk
For more information about Upstream, visit: http://www.move-upstream.org.uk/
For more information about MediSieve, visit: https://www.medisieve.com/
For further details about the Hammersmith & Fulham Brilliant Business Awards, visit http://hfbrill4biz.com/

 

Follow redheadPR on Twitter and like them on Facebook
Visit www.redheadpr.co.uk
Find out more about founder and managing director, Sara Tye